These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 6163328)

  • 21. The antitumor effect of interferon against murine osteogenic sarcoma.
    Satomi H
    Nihon Seikeigeka Gakkai Zasshi; 1983 Feb; 57(2):199-213. PubMed ID: 6189927
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intact interferon signaling in peripheral blood leukocytes of high-grade osteosarcoma patients.
    Buddingh EP; Ruslan SE; Berghuis D; Gelderblom H; Anninga JK; Hogendoorn PC; Egeler RM; Schilham MW; Lankester AC
    Cancer Immunol Immunother; 2012 Jun; 61(6):941-7. PubMed ID: 22402907
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enhancement of antitumor immunity by combining anti-cytotoxic T lymphocyte antigen-4 antibodies and cryotreated tumor lysate-pulsed dendritic cells in murine osteosarcoma.
    Kawano M; Itonaga I; Iwasaki T; Tsumura H
    Oncol Rep; 2013 Mar; 29(3):1001-6. PubMed ID: 23291864
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunotherapeutic approaches in pediatric osteosarcoma.
    Cao H; Zhang H; Zou H
    Minerva Pediatr; 2018 Dec; 70(6):635-636. PubMed ID: 28353326
    [No Abstract]   [Full Text] [Related]  

  • 25. Interferon-neutralizing antibodies in a patient treated with human fibroblast interferon.
    Vallbracht A; Treuner J; Flehmig B; Joester KE; Niethammer D
    Nature; 1981 Feb; 289(5797):496-7. PubMed ID: 6162104
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of osteosarcoma by interferon and differentiated surgery.
    Nilsonne U
    Sem Hop; 1982 Sep; 58(30-31):1764-6. PubMed ID: 6182617
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of human leukocyte interferon on the growth of human osteosarcoma cells in tissue culture.
    Strander H; Einhorn S
    Int J Cancer; 1977 Apr; 19(4):468-73. PubMed ID: 265297
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Progress and opportunities for immune therapeutics in osteosarcoma.
    Lettieri CK; Appel N; Labban N; Lussier DM; Blattman JN; Hingorani P
    Immunotherapy; 2016 Oct; 8(10):1233-44. PubMed ID: 27605071
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of CTLA-4 and PD-1 in anti-tumor immune response and their potential efficacy against osteosarcoma.
    Wang SD; Li HY; Li BH; Xie T; Zhu T; Sun LL; Ren HY; Ye ZM
    Int Immunopharmacol; 2016 Sep; 38():81-9. PubMed ID: 27258185
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The preparation of antibodies directed against human immune interferon.
    De Ley M; Van Damme J; Billiau A; De Somer P
    J Virol Methods; 1981 Oct; 3(3):149-53. PubMed ID: 6170651
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Applying Osteosarcoma Immunology to Understand Disease Progression and Assess Immunotherapeutic Response.
    Pratt HG; Justin EM; Lindsey BA
    Adv Exp Med Biol; 2020; 1258():91-109. PubMed ID: 32767236
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Interferon/Controlled study in 3-year survival of patients with osteosarcoma (author's transl)].
    Kotz R; Plattner E; Ramach W; Flener R; Bodo G
    Arzneimittelforschung; 1982; 32(4):446-8. PubMed ID: 6179524
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Purification of human interferons by antibody affinity chromatography.
    Berg K; Alacam R; Hamilton RD; Heron I
    Tex Rep Biol Med; 1977; 35():187-92. PubMed ID: 358447
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Does successful interferon treatment of tumor patients require life-long treatment?
    Strander H; Boëthius J; Erhardt K; Haglund S; Hindmarsh T; Johansson B; Nilsonne U; Szamosi A
    J Interferon Res; 1987 Oct; 7(5):619-26. PubMed ID: 3479501
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The status of interferon.
    Burke DC
    Sci Am; 1977 Apr; 236(4):42-50. PubMed ID: 265626
    [No Abstract]   [Full Text] [Related]  

  • 36. Increased PD-L1 and T-cell infiltration in the presence of HLA class I expression in metastatic high-grade osteosarcoma: a rationale for T-cell-based immunotherapy.
    Sundara YT; Kostine M; Cleven AH; Bovée JV; Schilham MW; Cleton-Jansen AM
    Cancer Immunol Immunother; 2017 Jan; 66(1):119-128. PubMed ID: 27853827
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Acute infections in interferon-treated patients with osteosarcoma: preliminary report of a comparative study.
    Strander H; Cantell K; Carlström G; Ingimarsson S; Jakobsson P; Nilsonne U
    J Infect Dis; 1976 Jun; 133 Suppl():A245-8. PubMed ID: 1064674
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Anti-viral and anti-neoplastic actions of interferon--with special reference to its clinical application].
    Imanishi J
    Nihon Rinsho; 1980 Sep; 38(9):3272-81. PubMed ID: 6166771
    [No Abstract]   [Full Text] [Related]  

  • 39. Auto T cells expressing chimeric antigen receptor derived from auto antibody might be a new treatment for osteosarcoma.
    Weibo P; Zhaoming Y
    Med Hypotheses; 2012 May; 78(5):616-8. PubMed ID: 22330890
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Surgical treatment of bone tumors in conjunction with microwave-induced hyperthermia and adjuvant immunotherapy. A preliminary report.
    Fan Q; Ma B; Guo A; Li Y; Ye J; Zhou Y; Qiu X
    Chin Med J (Engl); 1996 Jun; 109(6):425-31. PubMed ID: 9206073
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.